{"id":59874,"date":"2024-08-20T19:05:10","date_gmt":"2024-08-20T17:05:10","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/paragonix-technologies-launches-new-molecular-diagnostics-study-to-expand-data-collection-in-post-transplant-monitoring\/"},"modified":"2024-08-20T19:05:10","modified_gmt":"2024-08-20T17:05:10","slug":"paragonix-technologies-launches-new-molecular-diagnostics-study-to-expand-data-collection-in-post-transplant-monitoring","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/paragonix-technologies-launches-new-molecular-diagnostics-study-to-expand-data-collection-in-post-transplant-monitoring\/","title":{"rendered":"Paragonix Technologies Launches New Molecular Diagnostics Study to Expand Data Collection in Post-Transplant Monitoring"},"content":{"rendered":"<div>\n<p>\n<b><i>Organ preservation company enhances GUARDIAN-Heart transplant study to explore impact of advanced preservation on organ rejection and hospital readmission rates<\/i><\/b><\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20240820273922\/en\/1194317\/5\/Blue_Logo_with_Tagline.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20240820273922\/en\/1194317\/22\/Blue_Logo_with_Tagline.jpg\"><\/a><br \/><a href=\"https:\/\/mms.businesswire.com\/media\/20240820273922\/en\/1194317\/5\/Blue_Logo_with_Tagline.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20240820273922\/en\/1194317\/21\/Blue_Logo_with_Tagline.jpg\"><\/a><\/p>\n<p>WALTHAM, Mass.&#8211;(BUSINESS WIRE)&#8211;<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.paragonixtechnologies.com%2F&amp;esheet=54111633&amp;newsitemid=20240820273922&amp;lan=en-US&amp;anchor=Paragonix+Technologies&amp;index=1&amp;md5=769ec5bb0cfb590c4e6a5f38d6041e45\" rel=\"nofollow noopener\" shape=\"rect\">Paragonix Technologies<\/a>, a leading organ transplant company, has announced the expansion of its GUARDIAN Registry with the introduction of a new sub-study in the cardiac branch of research. This initiative will further enhance the understanding and management of post-transplant rejection, with a particular focus on molecular diagnostics. For the first time, this large scale data collection effort connects the major data sets in pre, peri, and post transplantation: donor organ data, preservation data, post-operative outcomes, survival and \u2013 uniquely \u2013 post-transplant rejection data.<\/p>\n<p>\n\u201cThis GUARDIAN-Heart sub-study will add data that may prove pivotal for the future of heart transplants,\u201d said Dr. Kiran Khush, Professor of Medicine, Director of Heart Transplant Research, and transplant cardiologist at Stanford Health Care. \u201cUnderstanding the nuances of post-transplant recovery and the factors influencing patient outcomes will enable us to tailor treatments more effectively. Our goal is to reduce complications, lower readmission rates, and ultimately ensure that transplant patients have the best possible quality of life.\u201d<\/p>\n<p>\nThe GUARDIAN study is the world\u2019s largest post-market, observational registry of over 3,500 organ transplant recipient patients whose donor organs were preserved and transported using Paragonix Advanced Organ Preservation Systems. The study has collected millions of data points on clinical outcomes, post-transplant complications, and patient survival to help enhance the understanding and management of organ transplant care.<\/p>\n<p>\nThe addition of a molecular diagnostics sub-study will allow GUARDIAN investigators to gather comprehensive data on rejection and readmission rates captured throughout the subsequent 12-month period following a heart transplant. Expanding upon extensive data acquired from the pre- and post-operative to the discharge phase, this study will now encompass the crucial post-discharge period, providing patient insights over a full year. The data collected will encompass biopsies, cell-free DNA (cfDNA), gene expression profiling (GEP), Molecular Microscope Diagnostic System (MMDx), renal replacement therapy (RRT), and readmission interventions.<\/p>\n<p>\n\u201cWe thank GUARDIAN Clinical Investigators and our transplant partners for initiating this new study to provide deeper insights into the long-term outcomes of transplant patients,\u201d said Dr. Lisa Anderson, CEO of Paragonix. \u201cThe planned analyses will provide data to better understand the impact of preservation on organ rejection and improve post-transplant care for patients.\u201d<\/p>\n<p>\nFor more information about the GUARDIAN Registry, please visit <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.paragonix.com&amp;esheet=54111633&amp;newsitemid=20240820273922&amp;lan=en-US&amp;anchor=www.paragonix.com&amp;index=2&amp;md5=2fef1b90e08e54e6f844eb605be61ae1\" rel=\"nofollow noopener\" shape=\"rect\">www.paragonix.com<\/a>.<\/p>\n<p>\n<b>About Paragonix Technologies<\/b><\/p>\n<p>\nParagonix Technologies is a leading developer, manufacturer, and service provider in the organ transplant industry, establishing a novel approach to organ preservation.<\/p>\n<p>\nParagonix Technologies provides Advanced Organ Preservation (\u201cAOP\u201d) devices that safeguard donor organs during the journey between donor and recipient patients. Our FDA-cleared and CE-marked devices incorporate clinically proven and medically trusted cold preservation techniques that allow unprecedented physical and thermal protection to the organ during transit. All Paragonix AOP devices are natively integrated with our novel digital app, delivering real-time organ tracking data and monitoring logistics for transplant teams seeking a secure and centralized solution. For more information, visit <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.paragonix.com&amp;esheet=54111633&amp;newsitemid=20240820273922&amp;lan=en-US&amp;anchor=www.paragonix.com&amp;index=3&amp;md5=1cbf0bb5cc7ccfa2cb758f35ce984835\" rel=\"nofollow noopener\" shape=\"rect\">www.paragonix.com<\/a>.<\/p>\n<p>\nFollow us on Twitter: <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2Fparagonixsherpa&amp;esheet=54111633&amp;newsitemid=20240820273922&amp;lan=en-US&amp;anchor=%40ParagonixSherpa&amp;index=4&amp;md5=bbf2c8dff98a48a04caa7f87921c72c3\" rel=\"nofollow noopener\" shape=\"rect\">@ParagonixSherpa<\/a><br \/>Connect with us on LinkedIn: <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fparagonix%2F&amp;esheet=54111633&amp;newsitemid=20240820273922&amp;lan=en-US&amp;anchor=Paragonix+Technologies&amp;index=5&amp;md5=38d0e51f28c38830ecd6dfc8c01065ff\" rel=\"nofollow noopener\" shape=\"rect\">Paragonix Technologies<\/a><br \/>Like Us on Facebook: <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.facebook.com%2Fparagonixsherpa%2F&amp;esheet=54111633&amp;newsitemid=20240820273922&amp;lan=en-US&amp;anchor=Paragonix+Technologies&amp;index=6&amp;md5=d35844d39d07f34645d29d5f339d2599\" rel=\"nofollow noopener\" shape=\"rect\">Paragonix Technologies<\/a><\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\n<b>Media Contact:\u00a0 <\/b>Adam Lafreniere, Vice President, Marketing<br \/>\n<br \/><a target=\"_blank\" href=\"&#x6d;&#x61;&#105;l&#x74;&#x6f;&#58;&#109;a&#x72;&#x6b;&#101;&#116;i&#x6e;&#x67;&#64;pa&#x72;&#x61;&#103;o&#x6e;&#x69;&#120;&#116;e&#x63;&#x68;&#110;&#111;l&#x6f;&#x67;&#105;es&#x2e;&#x63;&#111;m\" rel=\"nofollow noopener\" shape=\"rect\">&#x6d;&#97;r&#x6b;&#x65;&#116;i&#x6e;&#103;&#64;&#x70;&#x61;&#114;a&#x67;&#111;n&#x69;&#x78;&#116;e&#x63;&#x68;&#110;&#x6f;&#x6c;&#111;g&#x69;&#x65;&#115;&#46;&#x63;&#111;m<\/a><br \/>L-656, Ver 0<\/p>\n<p>\n\u00a0<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Organ preservation company enhances GUARDIAN-Heart transplant study to explore impact of advanced preservation on organ rejection and hospital readmission rates WALTHAM, Mass.&#8211;(BUSINESS WIRE)&#8211;Paragonix Technologies, a leading organ transplant company, has announced the expansion of its GUARDIAN Registry with the introduction of a new sub-study in the cardiac branch of research. This initiative will further enhance &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/paragonix-technologies-launches-new-molecular-diagnostics-study-to-expand-data-collection-in-post-transplant-monitoring\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-59874","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Paragonix Technologies Launches New Molecular Diagnostics Study to Expand Data Collection in Post-Transplant Monitoring - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/paragonix-technologies-launches-new-molecular-diagnostics-study-to-expand-data-collection-in-post-transplant-monitoring\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Paragonix Technologies Launches New Molecular Diagnostics Study to Expand Data Collection in Post-Transplant Monitoring - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Organ preservation company enhances GUARDIAN-Heart transplant study to explore impact of advanced preservation on organ rejection and hospital readmission rates WALTHAM, Mass.&#8211;(BUSINESS WIRE)&#8211;Paragonix Technologies, a leading organ transplant company, has announced the expansion of its GUARDIAN Registry with the introduction of a new sub-study in the cardiac branch of research. This initiative will further enhance ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/paragonix-technologies-launches-new-molecular-diagnostics-study-to-expand-data-collection-in-post-transplant-monitoring\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2024-08-20T17:05:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20240820273922\/en\/1194317\/22\/Blue_Logo_with_Tagline.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/paragonix-technologies-launches-new-molecular-diagnostics-study-to-expand-data-collection-in-post-transplant-monitoring\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/paragonix-technologies-launches-new-molecular-diagnostics-study-to-expand-data-collection-in-post-transplant-monitoring\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Paragonix Technologies Launches New Molecular Diagnostics Study to Expand Data Collection in Post-Transplant Monitoring\",\"datePublished\":\"2024-08-20T17:05:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/paragonix-technologies-launches-new-molecular-diagnostics-study-to-expand-data-collection-in-post-transplant-monitoring\\\/\"},\"wordCount\":543,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/paragonix-technologies-launches-new-molecular-diagnostics-study-to-expand-data-collection-in-post-transplant-monitoring\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20240820273922\\\/en\\\/1194317\\\/22\\\/Blue_Logo_with_Tagline.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/paragonix-technologies-launches-new-molecular-diagnostics-study-to-expand-data-collection-in-post-transplant-monitoring\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/paragonix-technologies-launches-new-molecular-diagnostics-study-to-expand-data-collection-in-post-transplant-monitoring\\\/\",\"name\":\"Paragonix Technologies Launches New Molecular Diagnostics Study to Expand Data Collection in Post-Transplant Monitoring - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/paragonix-technologies-launches-new-molecular-diagnostics-study-to-expand-data-collection-in-post-transplant-monitoring\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/paragonix-technologies-launches-new-molecular-diagnostics-study-to-expand-data-collection-in-post-transplant-monitoring\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20240820273922\\\/en\\\/1194317\\\/22\\\/Blue_Logo_with_Tagline.jpg\",\"datePublished\":\"2024-08-20T17:05:10+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/paragonix-technologies-launches-new-molecular-diagnostics-study-to-expand-data-collection-in-post-transplant-monitoring\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/paragonix-technologies-launches-new-molecular-diagnostics-study-to-expand-data-collection-in-post-transplant-monitoring\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/paragonix-technologies-launches-new-molecular-diagnostics-study-to-expand-data-collection-in-post-transplant-monitoring\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20240820273922\\\/en\\\/1194317\\\/22\\\/Blue_Logo_with_Tagline.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20240820273922\\\/en\\\/1194317\\\/22\\\/Blue_Logo_with_Tagline.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/paragonix-technologies-launches-new-molecular-diagnostics-study-to-expand-data-collection-in-post-transplant-monitoring\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Paragonix Technologies Launches New Molecular Diagnostics Study to Expand Data Collection in Post-Transplant Monitoring\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Paragonix Technologies Launches New Molecular Diagnostics Study to Expand Data Collection in Post-Transplant Monitoring - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/paragonix-technologies-launches-new-molecular-diagnostics-study-to-expand-data-collection-in-post-transplant-monitoring\/","og_locale":"en_US","og_type":"article","og_title":"Paragonix Technologies Launches New Molecular Diagnostics Study to Expand Data Collection in Post-Transplant Monitoring - Pharma Trend","og_description":"Organ preservation company enhances GUARDIAN-Heart transplant study to explore impact of advanced preservation on organ rejection and hospital readmission rates WALTHAM, Mass.&#8211;(BUSINESS WIRE)&#8211;Paragonix Technologies, a leading organ transplant company, has announced the expansion of its GUARDIAN Registry with the introduction of a new sub-study in the cardiac branch of research. This initiative will further enhance ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/paragonix-technologies-launches-new-molecular-diagnostics-study-to-expand-data-collection-in-post-transplant-monitoring\/","og_site_name":"Pharma Trend","article_published_time":"2024-08-20T17:05:10+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20240820273922\/en\/1194317\/22\/Blue_Logo_with_Tagline.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/paragonix-technologies-launches-new-molecular-diagnostics-study-to-expand-data-collection-in-post-transplant-monitoring\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/paragonix-technologies-launches-new-molecular-diagnostics-study-to-expand-data-collection-in-post-transplant-monitoring\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Paragonix Technologies Launches New Molecular Diagnostics Study to Expand Data Collection in Post-Transplant Monitoring","datePublished":"2024-08-20T17:05:10+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/paragonix-technologies-launches-new-molecular-diagnostics-study-to-expand-data-collection-in-post-transplant-monitoring\/"},"wordCount":543,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/paragonix-technologies-launches-new-molecular-diagnostics-study-to-expand-data-collection-in-post-transplant-monitoring\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20240820273922\/en\/1194317\/22\/Blue_Logo_with_Tagline.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/paragonix-technologies-launches-new-molecular-diagnostics-study-to-expand-data-collection-in-post-transplant-monitoring\/","url":"https:\/\/pharma-trend.com\/en\/paragonix-technologies-launches-new-molecular-diagnostics-study-to-expand-data-collection-in-post-transplant-monitoring\/","name":"Paragonix Technologies Launches New Molecular Diagnostics Study to Expand Data Collection in Post-Transplant Monitoring - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/paragonix-technologies-launches-new-molecular-diagnostics-study-to-expand-data-collection-in-post-transplant-monitoring\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/paragonix-technologies-launches-new-molecular-diagnostics-study-to-expand-data-collection-in-post-transplant-monitoring\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20240820273922\/en\/1194317\/22\/Blue_Logo_with_Tagline.jpg","datePublished":"2024-08-20T17:05:10+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/paragonix-technologies-launches-new-molecular-diagnostics-study-to-expand-data-collection-in-post-transplant-monitoring\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/paragonix-technologies-launches-new-molecular-diagnostics-study-to-expand-data-collection-in-post-transplant-monitoring\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/paragonix-technologies-launches-new-molecular-diagnostics-study-to-expand-data-collection-in-post-transplant-monitoring\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20240820273922\/en\/1194317\/22\/Blue_Logo_with_Tagline.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20240820273922\/en\/1194317\/22\/Blue_Logo_with_Tagline.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/paragonix-technologies-launches-new-molecular-diagnostics-study-to-expand-data-collection-in-post-transplant-monitoring\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Paragonix Technologies Launches New Molecular Diagnostics Study to Expand Data Collection in Post-Transplant Monitoring"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/59874","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=59874"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/59874\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=59874"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=59874"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=59874"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}